Sugi Predict

Sugi Predict / Compounds / SCHEMBL20399682

SCHEMBL20399682

SCHEMBL20399682

CCOC(=O)c1ncc(C)cc1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JMJD6 Q6NYC1 1/20 0.43
▸ CYP2C9 P11712 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ NPC1 O15118 3/20 0.41
▸ ALDH1A1 P00352 3/20 0.41
▸ NPSR1 Q6W5P4 2/20 0.41
▸ TP53 P04637 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ XBP1 P17861 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ TLR9 Q9NR96 1/20 0.41
▸ RAB9A P51151 2/20 0.40
▸ GABRA1 P14867 1/20 0.40
▸ GABRG2 P18507 1/20 0.40
▸ GABRB3 P28472 1/20 0.40
▸ GABRA5 P31644 1/20 0.40
▸ GABRA3 P34903 1/20 0.40
▸ GABRA2 P47869 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30697102 1.00 JMJD6 (0.43) JMJD6CYP2C9CYP2C19NPC1ALDH1A1
SCHEMBL24880001 0.89 ALDH1A1 (0.40) JMJD6ALDH1A1MAPTGABRA1GABRG2
SCHEMBL29664441 0.87 THRB (0.43) JMJD6CYP2C9CYP2C19NPC1ALDH1A1
SCHEMBL4018903 0.87 THRB (0.43) JMJD6CYP2C9CYP2C19NPC1ALDH1A1
SCHEMBL15968597 0.85 CA12 (0.46) JMJD6CYP2C9CYP2C19NPC1ALDH1A1
SCHEMBL6559030 0.85 TSHR (0.47) CYP2C9CYP2C19NPC1ALDH1A1NPSR1
SCHEMBL29859779 0.85 TSHR (0.47) CYP2C9CYP2C19NPC1ALDH1A1NPSR1
SCHEMBL7684716 0.84 S1PR1 (0.49) JMJD6CYP2C9CYP2C19NPC1ALDH1A1
SCHEMBL17362538 0.84 TARBP2 (0.42) JMJD6CYP2C9CYP2C19NPC1ALDH1A1
SCHEMBL15431711 0.83 ATM (0.47) NPC1ALDH1A1NPSR1MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12545662-B2 MK2 inhibitors and uses thereof XINTHERA, INC. (US) 2026-02-10 — — US disclosed
US-12139462-B2 Pyridinone MK2 inhibitors and uses thereof XINTHERA, INC. (US) 2024-11-12 — — US disclosed
US-11987574-B2 MK2 inhibitors and uses thereof XINTHERA, INC. (US) 2024-05-21 — — US disclosed
EP-4367099-A1 PYRIDINONE MK2 INHIBITORS AND USES THEREOF Xinthera, Inc. (US) 2024-05-15 — — EP disclosed
US-20240092795-A1 PYRIDINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS Revolution Medicines, Inc. 2024-03-21 — — US disclosed
CN-117651698-A Pyridone MK2 inhibitors and uses thereof 新特拉有限公司 2024-03-05 — — CN disclosed
EP-4313970-A1 MK2 INHIBITORS AND USES THEREOF Xinthera, Inc. (US) 2024-02-07 — — EP disclosed
US-20230382864-A1 PYRIDINONE MK2 INHIBITORS AND USES THEREOF XINTHERA, INC. 2023-11-30 — — US disclosed
US-20230382864-A1 PYRIDINONE MK2 INHIBITORS AND USES THEREOF XINTHERA, INC. 2023-11-30 — — US disclosed
US-20230382864-A1 PYRIDINONE MK2 INHIBITORS AND USES THEREOF XINTHERA, INC. 2023-11-30 — — US disclosed
US-11680056-B2 MK2 inhibitors and uses thereof XINTHERA, INC. (US) 2023-06-20 — — US disclosed
US-11673896-B2 Pyridine compounds as allosteric SHP2 inhibitors Revolution Medicines, Inc. (US) 2023-06-13 — — US disclosed
EP-3571189-B1 PYRIDINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS REVOLUTION MEDICINES INC (US) 2023-03-29 — — EP disclosed
US-20230053465-A1 PYRIDINONE MK2 INHIBITORS AND USES THEREOF XINTHERA, INC. 2023-02-23 — — US disclosed
US-20230053465-A1 PYRIDINONE MK2 INHIBITORS AND USES THEREOF XINTHERA, INC. 2023-02-23 — — US disclosed
WO-2023283338-A1 PYRIDINONE MK2 INHIBITORS AND USES THEREOF XINTHERA, INC. (US) 2023-01-12 — — WO disclosed
US-20220402892-A1 MK2 INHIBITORS AND USES THEREOF XINTHERA, INC. 2022-12-22 — — US disclosed
WO-2022212489-A1 MK2 INHIBITORS AND USES THEREOF XINTHERA, INC. (US) 2022-10-06 — — WO disclosed
WO-2022109481-A1 METHODS OF SYNTHESIZING SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS ACLARIS THERAPEUTICS, INC. (US) 2022-05-27 — — WO disclosed
WO-2018136264-A1 PYRIDINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS Revolution Medicines, Inc. (US) 2018-07-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12139462-B2 Pyridinone MK2 inhibitors and uses thereof ENPP2, PLP2, PDXK JMJD6 1271/4885CYP2C9 2754/4885CYP2C19 1723/4885
US-11987574-B2 MK2 inhibitors and uses thereof MKNK2, ENPP2, MAPKAPK2 JMJD6 1325/4885CYP2C9 4314/4885CYP2C19 3770/4885
US-20230053465-A1 PYRIDINONE MK2 INHIBITORS AND USES THEREOF ENPP2, PLP2, PDXK JMJD6 1271/4885CYP2C9 2754/4885CYP2C19 1723/4885
US-20230382864-A1 PYRIDINONE MK2 INHIBITORS AND USES THEREOF ENPP2, PLP2, PDXK JMJD6 1271/4885CYP2C9 2754/4885CYP2C19 1723/4885
US-11680056-B2 MK2 inhibitors and uses thereof MKNK2, ENPP2, MAPKAPK2 JMJD6 1325/4885CYP2C9 4314/4885CYP2C19 3770/4885
US-20220402892-A1 MK2 INHIBITORS AND USES THEREOF MKNK2, ENPP2, MAPKAPK2 JMJD6 1208/4885CYP2C9 4661/4885CYP2C19 4391/4885
US-11673896-B2 Pyridine compounds as allosteric SHP2 inhibitors PTPN1, PTPN18, PTPN2 JMJD6 1396/4885CYP2C9 3213/4885CYP2C19 3826/4885
US-20240092795-A1 PYRIDINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS PTPN1, PTPN18, PTPN2 JMJD6 1396/4885CYP2C9 3213/4885CYP2C19 3826/4885
US-12545662-B2 MK2 inhibitors and uses thereof NR3C2, NR2C2, AGTR2 JMJD6 811/4885CYP2C9 2486/4885CYP2C19 2704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.